Olema Pharmaceuticals, Inc. OLMA Proceeds From Issuance Of Shares Upon Follow On Public Offering
Proceeds From Issuance Of Shares Upon Follow On Public Offering at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept olma:ProceedsFromIssuanceOfSharesUponFollowOnPublicOffering.
The official record: Olema Pharmaceuticals, Inc.’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →
Ask your AI about Olema Pharmaceuticals, Inc.'s proceeds from issuance of shares upon follow on public offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Olema Pharmaceuticals, Inc.'s proceeds from issuance of shares upon follow on public offering?
- Olema Pharmaceuticals, Inc. (OLMA) reported proceeds from issuance of shares upon follow on public offering of $51.35M in Q4 2025.
- What does proceeds from issuance of shares upon follow on public offering mean?
- This represents the cash inflows generated from the sale of additional common stock to the public after the initial public offering. It is a primary mechanism for clinical-stage biopharmaceutical companies to raise capital to fund ongoing research and development activities. High proceeds indicate strong market access to capital for pipeline advancement.